Visiting Dana-Farber? See our prescreening and mask requirements.
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Clinicians at Dana-Farber Brigham Cancer Center's Hematologic Malignancies Program hold presidency and leadership roles in national organizations, provide editorial oversight of influential journals, and are teachers in the field.
Some of our affiliations and accreditations include:
Program Accreditations, Registrations, Licenses Foundation for the Accreditation of Cellular Therapy (FACT) for stem cell transplant and immune effector cell therapies U.S. Food and Drug Administration American Association of Blood Banks (AABB) Centers for Medicare and Medicaid Services The Joint Commission Fully accredited by the National Marrow Donor Program (NMDP)
Clinical Key member of the Alliance for Clinical Trials in Oncology's Multiple Myeloma Committee Founding institution of the Multiple Myeloma Research Consortium (MMRC) Member of the Center for International Blood and Marrow Transplant Research (CIBMTR), serving on working committees and the Executive Committee Member of the Alliance for Clinical Trials in Oncology (formerly CALGB) Charter Member of the Blood and Marrow Transplant Clinical Trials Network of the National Institutes of Health (BMT-CTN) Accredited by Center for Medicare and Medicaid Services (CMS) Clinical Laboratory Improvement Amendment (CLIA) Our HM/HSCT staff includes more than 45 physicians and 20 nurses, plus approximately 20 mid-level practitioners.
Nursing Awarded Magnet® designation by American Nurses Credentialing Center Disease Attacking the Immune System (DAISY) Foundation award participant
Administrative Teaching affiliate of Harvard Medical School Member of Dana-Farber/Harvard Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center Responsible for oversight of the National Comprehensive Cancer Network (NCCN) clinical practice guidelines Food and Drug Administration (FDA)-registered Joint Commission Hospital accreditation Joint Commission Laboratory accreditation Staff leadership and participation in national organizations, including: American Society for Transplantation and Cellular therapy (ASTCT) American Society of Hematology (ASH) Lymphoma Research Foundation (LRF) Scientific Advisory Board Board of Scientific Advisors of the National Cancer Institute (NCI) National Marrow Donor Program Center for International Blood and Marrow Transplant Research International Myeloma Working Group